To evaluate periodontal inflamed surface area, serum Interleukin12, Interleukin18 levels in Stage III periodontitis patients with & without Type 2 Diabetes Mellitus

Not Applicable

• Conditions: Health Condition 1: K053- Chronic periodontitisHealth Condition 2: K053- Chronic periodontitis

• Registration Number: CTRI/2023/06/053653
• Lead Sponsor: none

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Group I Periodontally healthy patients GI is equal to0 probing depth PPD less than or equal to 3 mm CAL is equal to 0 with no radiographic evidence of bone loss

Group II Stage III periodontitis with GI greater than 1 PPD more than or equal to 6mm and CAL more than or equal to 5mm

Group III Stage III periodontitis with T2DM patients GI more than 1 PPD more than or equal to 6mm and CAL more than or equal to 5mm HbA1c levels between 5 to 7 percent

Exclusion Criteria

Patients who have undergone any periodontal therapy in the past 6 months

Patients with symptoms of acute illness

Patients who are on immunosuppressive therapy

Systemic anti inflammatory treatment within the previous 3 months or regular use of specific drugs known to affect periodontal tissues

Pregnant women and lactating mothers

Study & Design

• Study Type: Observational
• Study Design: Not specified